142 related articles for article (PubMed ID: 17510755)
1. Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization.
Richardson CH; de Matas M; Hosker H; Mukherjee R; Wong I; Chrystyn H
Pharm Res; 2007 Nov; 24(11):2008-17. PubMed ID: 17510755
[TBL] [Abstract][Full Text] [Related]
2. Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler.
Hindle M; Peers EM; Parry-Billings M; Chrystyn H
Br J Clin Pharmacol; 1997 Mar; 43(3):336-8. PubMed ID: 9088593
[TBL] [Abstract][Full Text] [Related]
3. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation.
Chege JK; Chrystyn H
Respir Med; 2000 Jan; 94(1):51-6. PubMed ID: 10714479
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks.
de Matas M; Shao Q; Richardson CH; Chrystyn H
Eur J Pharm Sci; 2008 Jan; 33(1):80-90. PubMed ID: 18035525
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler.
Moore A; Riddell K; Joshi S; Chan R; Mehta R
J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):164-172. PubMed ID: 28170282
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler.
Kemp JP; Hill MR; Vaughan LM; Meltzer EO; Welch MJ; Ostrom NK
Ann Allergy Asthma Immunol; 1997 Oct; 79(4):322-6. PubMed ID: 9357377
[TBL] [Abstract][Full Text] [Related]
8. Clinical and functional responses to salbutamol inhaled via different devices in asthmatic patients with induced bronchoconstriction.
Lavorini F; Geri P; Luperini M; Maluccio NM; Mariani L; Marmai C; Pistolesi M; Fontana GA
Br J Clin Pharmacol; 2004 Nov; 58(5):512-20. PubMed ID: 15521899
[TBL] [Abstract][Full Text] [Related]
9. Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization.
Silkstone VL; Corlett SA; Chrystyn H
Br J Clin Pharmacol; 2002 Aug; 54(2):115-9. PubMed ID: 12207629
[TBL] [Abstract][Full Text] [Related]
10. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
[TBL] [Abstract][Full Text] [Related]
11. Agreement between two methods for assessing bioequivalence of inhaled salbutamol.
Lavorini F; Geri P; Camiciottoli G; Pistolesi M; Fontana GA
Pulm Pharmacol Ther; 2008; 21(2):380-4. PubMed ID: 17997115
[TBL] [Abstract][Full Text] [Related]
12. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung.
Hindle M; Newton DA; Chrystyn H
Thorax; 1993 Jun; 48(6):607-10. PubMed ID: 8346489
[TBL] [Abstract][Full Text] [Related]
13. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol.
Clark DJ; Lipworth BJ
Br J Clin Pharmacol; 1996 Mar; 41(3):247-9. PubMed ID: 8866927
[TBL] [Abstract][Full Text] [Related]
14. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices.
Lipworth BJ; Clark DJ
Pulm Pharmacol Ther; 1997 Aug; 10(4):211-4. PubMed ID: 9695144
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged.
Silkstone VL; Tomlinson HS; Corlett SA; Chrystyn H
Br J Clin Pharmacol; 2000 Sep; 50(3):281-4. PubMed ID: 10971315
[TBL] [Abstract][Full Text] [Related]
16. Comparison of bronchodilating effects of two salbutamol dry powder inhalers in asthmatic patients.
Laurikainen K; Silvasti M; Calderon P; Lins R; Rosillon D
Arzneimittelforschung; 1997 Jan; 47(1):44-6. PubMed ID: 9037443
[TBL] [Abstract][Full Text] [Related]
17. Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices.
Lipworth BJ; Clark DJ
Eur J Clin Pharmacol; 1997; 53(1):47-9. PubMed ID: 9349929
[TBL] [Abstract][Full Text] [Related]
18. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices.
Hindle M; Chrystyn H
Thorax; 1994 Jun; 49(6):549-53. PubMed ID: 8016791
[TBL] [Abstract][Full Text] [Related]
19. Relative Lung and Systemic Bioavailability Along with Oropharyngeal Deposition of Salbutamol Post-Inhalation: A Pharmacokinetic Evaluation of Novel Inhaler Technique Training Gadgets.
Ammari WG; Sanders M
J Aerosol Med Pulm Drug Deliv; 2022 Oct; 35(5):278-285. PubMed ID: 35984934
[No Abstract] [Full Text] [Related]
20. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
